Home/Pipeline/VCR-036

VCR-036

Colorectal Cancer

PreclinicalActive

Key Facts

Indication

Colorectal Cancer

Phase

Preclinical

Status

Active

Company

Vicero Bio

About Vicero Bio

Vicero Bio is a private, preclinical-stage biotech developing next-generation cancer immunotherapies using its VINCOBODY platform. The platform leverages VHH (nanobody) fragments to create multi-specific biologics and antibody-drug conjugates (ADCs) designed for superior tumor penetration, reduced toxicity, and subcutaneous administration. Its lead candidate, VCR-036, is a bispecific targeting PD-1 and CTLA-4 for colorectal cancer, aiming to deliver combination efficacy without the typical severe side effects. The company is led by industry veterans with extensive experience in bringing blockbuster oncology drugs to market.

View full company profile

Therapeutic Areas

Oncology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active